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Abstract
Background: Urgent referral for suspected central nervous system (CNS) cancer is recommended, but little analysis
of the referral criteria diagnostic performance has been conducted. New 2015 NICE guidance recommends direct
brain imaging for patients with symptoms with positive predictive values (PPV) of 3 %, but further guidance is
needed.
Methods: A 12-month retrospective evaluation of 393 patients referred under previous 2005 NICE 2-week rule
criteria was conducted. Analysis was based on the three groups of symptoms forming the referral criteria, (1) CNS
symptoms, (2) recent onset headaches, (3) rapidly progressive subacute focal deficit/cognitive/behavioural/personality
change. Comparison was made with neuroimaging findings.
Results: Twelve (3.1 %) of 383 patients who attended clinic had CNS cancer suggesting the combination of clinical
judgement and application of 2005 criteria matched the 2015 guideline’s PPV threshold. PPVs for the three groups of
symptoms were (1) 4.1 % (95 % CIs 2.0 to 7.4 %), (2) 1.2 % (0.1 to 4.3 %) and (3) 3.7 % (0.1 to 19.0 %). Sensitivities were
(1) 83.3 % (95 % CIs 51.6 to 97.9 %), (2) 16.7 % (2.1 to 48.4 %), and (3) 8.3 % (0.2 to 38.5 %); specificities were (1)
37.2 % (32.3 to 42.3 %), (2) 55.5 % (50.3 to 60.7 %) and (3) 93.0 % (89.9 to 95.4 %). Of 288 patients who underwent
neuroimaging, 59 (20.5 %) had incidental findings, most commonly cerebrovascular disease.
Conclusions: The 2015 guidance is less prescriptive than previous criteria making clinical judgement more important.
CNS symptoms had greatest sensitivity, while PPVs for CNS symptoms and rapidly progressive subacute deficit/cognitive/
behavioural/personality change were closest to 3 %. Recent onset headaches had the lowest sensitivity and PPV.
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Background
The 1990s saw rising waiting times in the United Kingdom
(UK) for patients undergoing investigation of suspected
cancer, including suspected central nervous system (CNS)
cancer. This prompted the Department of Health to
introduce guidelines in 2000 for referral, with struc-
tured pathways and a waiting time target of 2 weeks
[1, 2]. The referral guidelines for suspected cancer were
revised in 2005 [3] and completely overhauled in 2015 [4]
because of concerns that cancer survival in the UK is
lower than in other developed countries. The latest guide-
lines for adults with suspected CNS cancer (Table 1),
which advocate direct referral for brain imaging to be per-
formed within 2 weeks, represent a substantial shift from
the 2005 guidelines (Table 2) which comprised clinical
criteria based on groups of symptoms for urgent out-
patient referral (typically to neurology) to be seen within
2 weeks, or for referral to be considered.
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Currently, the extent of implementation of the 2015
guidelines for suspected CNS cancer is somewhat variable,
with gradual transition being expected from the 2005 to
the 2015 guidelines while the implications for clinical
practice, including referral pathways and impact on im-
aging and reporting capacity etc., are understood.
The 2015 guidelines advise that adults with clinical
features that are associated with a positive predictive
value (PPV) of 3 % or more for CNS cancer should be
referred urgently for investigation [4]. The new guide-
lines are much less prescriptive in their wording, par-
ticularly, in respect of which clinical features might be
the most relevant. Relatively little is known about the
diagnostic performance of the 2005 referral criteria, or
diagnosis rate of CNS cancer among patients referred
using those criteria [5]. The likely effects of the 2015
guidelines upon referral behaviour and the implications
for direct access imaging requests is, to all intents and
purposes, unknown. An improved understanding of the
diagnostic performance of the 2005 criteria and which
clinical features are relevant in determining whether
there is a 3 % or greater likelihood of CNS cancer will
surely be helpful. In addition, relatively little is known
about the implications for patients and clinical pathways
upon the identification of incidental findings when im-
aging is being requested directly from primary care [6].
We have undertaken a retrospective study of patients
referred under the ‘2 week rule’ for suspected CNS can-
cer according to the 2005 guidelines over a 12 month
period. We have analysed (1) the diagnostic performance
of the 2005 criteria, with a clinical and radiological diag-
nosis of CNS cancer as the primary outcome, (2) the
symptom frequencies amongst all referred patients and
those with CNS cancer, and (3) incidental findings.
Methods
Data extraction and validation
Routine clinical data were extracted from referral letters,
clinic letters and imaging reports for all patients referred
under the ‘2 week rule’ for suspected CNS cancer to the
regional neurology service based at the Royal Preston
Hospital (serving a population of approximately 1.6 mil-
lion) between 1st June 2012 and 31st May 2013. Data
were extracted by one junior doctor (HM, who was an
undergraduate at the time of data collection), and were
independently validated by a second junior doctor (JB)
working in neurology. One year after data collection, all
patients’ records were reviewed to determine whether
any other visits/imaging had occurred.
Classification of 2005 referral criteria and analysis
Referral criteria (2005 criteria) were grouped as follows:
group 1 – symptoms related to the CNS (all new-onset
or recent-onset seizures were included in this group),
group 2 – headaches of recent onset accompanied by
features suggestive of raised intracranial pressure (ICP),
and group 3 – rapidly progressive subacute focal deficit/
cognitive/behavioural or personality change. Presenting
symptoms were classified into one of these three groups.
The primary outcome was the presence/absence of CNS
cancer on the basis of clinical assessment and, where
applicable, neuroimaging findings (CT brain/MRI brain).
Sensitivity, specificity, positive and negative predictive
values were calculated for each symptom group.
Statistical methods
Statistical analysis was performed using Stata (StataCorp.
2013. Stata Statistical Software: Release 13. College Sta-
tion, TX: StataCorp LP) and StatsDirect (StatsDirect Ltd.
StatsDirect statistical software. http://www.statsdirect.com.
England: StatsDirect Ltd. 2013).
Presenting symptoms were reported for all referrals
and by CNS cancer diagnosis using frequencies and per-
centages. Comparisons of presenting symptoms by CNS
cancer diagnosis were performed using the Fisher’s exact
Table 1 (From 2015 guidelines [4])
Consider an urgent direct access MRI scan of the brain (or CT scan if
MRI is contraindicated) (to be performed within 2 weeks) to assess for
brain or central nervous system cancer in adults with progressive,
sub-acute loss of central neurological function
Table 2 (From 2005 guidelines [3])
Refer urgently patients with:
• symptoms related to the CNS, including:
- progressive neurological deficit
- new-onset seizures
- headaches
- mental changes
- cranial nerve palsy
- unilateral sensorineural deafness
in whom a brain tumour is suspected
• headaches of recent onset accompanied by features suggestive of
raised intracranial pressure, for example:
- vomiting
- drowsiness
- posture-related headache
- pulse-synchronous tinnitus
or by other focal or non-focal neurological symptoms, for example
blackout, change in personality or memory
• a new, qualitatively different, unexplained headache that becomes
progressively severe
• suspected recent-onset seizures (refer to neurologist)
Consider urgent referral (to an appropriate specialist) in patients with
rapid progression of:
• subacute focal neurological deficit
• unexplained cognitive impairment, behavioural disturbance or
slowness, or a combination of these
• personality changes confirmed by a witness and for which there is
no reasonable explanation even in the absence of other symptoms
and signs of a brain tumour
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test. To avoid multiple testing, comparisons were made
only for the overall presenting symptom groups: symptoms
related to CNS cancer, headaches of recent onset accom-
panied by features suggestive of raised intracranial pressure
and consider urgent referral. The significance threshold
was set at p ≤ 0.05. Measures of diagnostic performance,
sensitivity, specificity, positive predictive value and nega-
tive predictive value were reported for each of the symp-
tom groups based on participants who were referred and
attended clinic. Diagnosis of CNS cancer was based on
clinical decision and radiological findings. Please see
Additional file 1: Appendix for raw data calculations.
Results
Between 1st June 2012 and 31st May 2013, 393 adult pa-
tients were referred under the ‘2 week rule’ for suspected
CNS cancer. Ten patients did not attend their appoint-
ment or were seen at another hospital. Three hundred
and eighty-three patients attended clinic, of whom 95 did
not undergo neuroimaging (and did not undergo imaging
by July 2014) on account of the neurologist considering
there to be no clinical suspicion of CNS cancer and no
other indication for scanning. Two hundred and eighty
eight patients underwent neuroimaging (Fig. 1).
CNS cancer diagnoses
Twelve patients were found to have CNS cancer. This
constitutes 3.1 % of the total number of referred patients
who attended their appointment and 4.2 % of patients
who underwent imaging. Histopathological diagnoses were
grade IV glioblastoma in 4 cases, lung cancer metastases in
2 cases, and anaplastic oligoastrocytoma in 1 case. No
biopsies were available in the remaining 5 cases. Radio-
logical and clinical diagnoses of these 5 cases were: cystic
glioma, metastases from unknown source in parasagittal
region, lung metastases in posterior corpus callosum, non-
small cell carcinoma metastases in right parietal tissue and
C2 vertebral body metastases without frank spinal cord
compression.
Diagnostic performance of 2005 referral criteria
The frequency of presenting symptoms and symptom
groups are shown in Table 3. Two hundred and forty-
three patients were referred with group 1 symptoms, 167
with group 2 symptoms, and 27 with group 3 symptoms.
For group 1 (symptoms related to the CNS), the sensitivity
was 83.3 % (95 % CI 51.6 to 97.9 %), specificity 37.2 %
(95 % CI 32.3 to 42.3 %), PPV 4.1 % (95 % CI 2.0 to 7.4 %)
and negative predictive value (NPV) 98.6 % (95 % CI 94.9
to 99.8 %). For group 2 (headaches of recent onset accom-
panied by features suggestive of raised intracranial pres-
sure), the sensitivity was 16.7 % (95 % CI 2.1 to 48.4 %),
specificity 55.5 % (95 % CI 50.3 to 60.7 %), PPV 1.2 %
(95 % CI 0.1 to 4.3 %) and NPV 95.4 % (95 % CI 91.7 to
97.8 %). For group 3 (rapidly progressive subacute focal
deficit/cognitive/behavioural or personality change), the
sensitivity was 8.3 % (95 % CI 0.2 to 38.5 %), specificity
93.0 % (95 % CI 89.9 to 95.4 %), PPV 3.7 % (95 % CI 0.1 to
19.0 %) and NPV 96.9 % (95 % CI 94.5 to 98.4 %).
Incidental findings
Of 288 patients who underwent neuroimaging, 59 (20.5 %)
were found to have incidental findings (Table 4). Cere-
brovascular disease (11.1 %), degenerative spine disease
(3.5 %) and sinus disease (3.1 %) were the most fre-
quent incidental findings.
Discussion
This study, to our knowledge, is the first to consider the
implications of the recently revised NICE guidelines for
suspected CNS cancer, and specifically which clinical
features are associated with a PPV of 3 % or more by
analysing the diagnostic performance of previous referral
criteria [5].
Anecdotally, there can appear to be excessive ‘2 week
rule’ referrals for suspected CNS cancer to neurology
clinics. With the 2015 guidelines advocating direct referral
for imaging, fewer patients with suspected CNS cancer
might be expected to attend neurology clinics, although
Fig. 1 Flow chart of patients recruited in the study
Mohammad et al. BMC Neurology  (2016) 16:152 Page 3 of 6
the identification of incidental findings will inevitably also
have implications for clinical care. In the present study,
‘2 week rule’ referrals constituted approximately 3 % of
the total number of new outpatient referrals to the re-
gional neurology service (ca. 12,000). The overall CNS
cancer diagnosis rate among the ‘2 week rule’ referral
population was 3.1 % (i.e. 12 CNS cancer diagnoses
among 383 patients who were referred by this route and
who attended clinic). This finding would appear to suggest
that intriguingly, through clinical judgement and the
application of the 2005 referral criteria, there was a pat-
tern of referral behaviour for suspected CNS cancer
matching the PPV threshold of 3 % at which patients
should be urgently referred, according to the 2015
guidelines [4].
Now that the referral criteria are much less prescriptive,
referrers will, more than ever, have to employ clinical
judgement when considering referral. But which clinical
features would suggest a PPV of 3 % or more? Headache
often tends to prompt concerns in the patient and the
referrer about the possibility of CNS cancer but performs
very poorly as a predictor [7]. Probably undue emphasis is
placed on headache per se, and the findings in the present
study support the usual view that as a single symptom it
does tend to be a poor discriminator with respect to the
presence/absence of CNS cancer. Nonetheless, headache
accounts for 4.4 % of primary care consultations and up
to 30 % of outpatient neurology referrals in the UK [8, 9].
However, the current analysis highlights focal deficits
(subacute or progressive), new-onset seizures, or cognitive/
behavioural/personality changes, as being more strongly
predictive of CNS cancer in the appropriate clinical con-
text. New-onset seizures in particular, whether focal or
secondary generalised, can be an important early manifest-
ation of a brain tumour. In a previous study of clinical
features and the risk of primary brain tumours, in which
Table 3 The prevalence of symptoms in referrals under the 2-week rule for suspected CNS cancer
Presenting symptom All referrals
(n = 383)
No CNS cancer
(n = 371)
CNS cancer
(n = 12)
p
Symptoms related to the CNS 243 (63.4) 233 (62.8) 10 (83.3) 0.224
Progressive neurological deficit 30 (7.8) 27 (7.3) 3 (25.0)
New-onset seizures 41 (10.7) 39 (10.5) 2 (16.7)
Headaches 173 (45.2) 168 (45.3) 5 (41.7)
Mental changes 21 (5.5) 19 (5.1) 2 (16.7)
Cranial nerve palsy 19 (5.0) 18 (4.9) 1 (8.3)
Unilateral sensorineural deafness 10 (2.6) 10 (2.7) 0 (0.0)
Headaches of recent onset accompanied by features suggestive of raised intracranial pressure 167 (43.6) 165 (44.5) 2 (16.7) 0.075
Vomiting 28 (7.3) 28 (7.5) 0 (0.0)
Drowsiness 23 (6.0) 23 (6.2) 0 (0.0)
Posture-related headache 68 (17.8) 67 (18.1) 1 (8.3)
Pulse-synchronous tinnitus 3 (0.8) 3 (0.8) 0 (0.0)
Other focal/non-focal neurological problems 71 (18.5) 70 (18.9) 1 (8.3)
New, qualitatively different, unexplained headache that becomes progressively severe 43 (11.2) 43 (11.6) 0 (0.0)
Consider urgent referral - rapidly progressive subacute focal deficit/cognitive/behavioural or
personality change
27 (7.0) 26 (7.0) 1 (8.3) 0.590
Subacute focal neurological deficit 7 (1.8) 6 (1.6) 1 (8.3)
Unexplained cognitive impairment/behavioural disturbance or slowness, or a combination
of these
17 (4.4) 17 (4.6) 0 (0.0)
Personality changes 9 (2.3) 9 (2.4) 0 (0.0)
p-value derived from Fisher’s Exact Test comparing presence of symptom groups between patients with and without confirmed CNS cancer
Table 4 Summary of incidental findings on neuroimaging
Incidental finding Number of patients (%)
Benign cystic lesion 5 (1.7 %)
Cerebrovascular disease 32 (11.1 %)
Small vessel disease only 25 (8.7 %)
Large artery disease only 5 (1.7 %)
Mixed small vessel and large artery disease 2 (0.7 %)
Degenerative spine disease 10 (3.5 %)
Cervical 9 (3.1 %)
Lumbar 1 (0.3 %)
CNS demyelination 3 (1.0 %)
Sinus disease 9 (3.1 %)
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new-onset epilepsy had an overall risk of 1.2 %, rising to
2.3 % if the patient was >60 years of age, in marked con-
trast to the risk with headache, which was associated with
a risk of less than 1 in 1000 [10].
It should be noted that diagnostic performance of all
three symptom groups in this study was poor by com-
parison with usual expectations for a good diagnostic
test which would have both a high sensitivity and speci-
ficity (both around 90.0 %) [11]. Headaches of recent
onset accompanied by features suggestive of raised ICP
were actually less frequent among patients found to have
CNS cancer than among the total referral population.
Potentially this suggests difficulties in clinical recogni-
tion of features of raised ICP. Uncertainty among refer-
rers over headache diagnosis has certainly been reported
previously [12].
Bypassing a neurology clinical opinion en route to brain
imaging may raise some issues in patient management,
particularly with respect to relative lack of a detailed
neurological assessment which, at least anecdotally, can
be helpful for contextualising incidental findings. Impact
of the NICE guidance with respect to imaging and report-
ing capacity is uncertain. An international report pub-
lished by the Organisation for Economic Cooperation and
Development (OECD) found that the UK had fewer mag-
netic resonance imaging (MRI) scanners than almost any
other Western country including developing countries
such as Turkey and Slovakia [13]. Out of 32 countries in
the OECD the UK stands 26th. For computerised tomog-
raphy (CT) scanning, the UK is 30th of 32 [13].
Brain scans are preferably reported by a neuroradiolo-
gist, which creates issues of hospital’s reporting capacity.
Implementation of the 2015 NICE criteria also needs
to take into account the frequent identification of inci-
dental findings. A systematic review and meta-analysis
reported incidental findings of 2.7 % from 19,559 partici-
pants [14]. The study suggested that at the very least
clinicians should counsel patients about the chance of
incidental findings prior to requesting a scan and that a
mechanism for their management would need to be
implemented [14]. There is considerable uncertainty sur-
rounding the management of some incidental findings
on brain imaging, including balancing risk/benefit of
intervention for intracranial aneurysms [15, 16], unrup-
tured arteriovenous malformations [17], low grade glioma
[18] and arachnoid cysts [14]. There is little evidence to
guide the management of incidental radiological cere-
brovascular disease. This lack of certainty can create
significant patient anxiety, lead to additional referrals/
investigations, sometimes with significant implications
for the patient [19–21]. It seems wise for pre-imaging
counselling to make reference not only to the possi-
bility of incidental findings but also uncertainty in
their management.
By necessity, given the study design, the calculation of
PPVs and NPVs is based on the referral population. This
does limit the extent to which these values are directly
applicable to the total population (i.e. including an un-
known number of unreferred patients with relevant symp-
toms). Clearly, the balance of positive and negative imaging
findings among unreferred patients is also unknown.
Conclusions
The new 2015 guidance is less prescriptive than previous
CNS cancer referral criteria making clinical judgement
even more important. Symptoms related to the CNS had
the greatest sensitivity, while PPVs for symptoms related
to the CNS and rapidly progressive subacute deficit/
cognitive/behavioural/personality change were closest
to the NICE referral figure of 3 %. Headaches of recent
onset had the lowest sensitivity and PPV; diagnostic
performance with respect to sensitivity and specificity
was poor for all three symptom groups. The frequent
occurrence of incidental findings also needs to be taken
into account when requesting imaging and planning
services.
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